CNBX - Cannabics Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2894
-0.0211 (-6.80%)
At close: 3:49PM EDT
Stock chart is not supported by your current browser
Previous Close0.3105
Open0.2900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2810 - 0.3350
52 Week Range0.2500 - 1.3500
Volume120,692
Avg. Volume91,009
Market Cap38.912M
Beta (3Y Monthly)-3.67
PE Ratio (TTM)20.67
EPS (TTM)0.0140
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga6 days ago

    'Algorithms Manage Everything': One Israeli Company's Mission To Make Marijuana Growing Effortless

    Cannabis cultivation is a meticulous process that involves more than just planting a seed or a clone and watering it regularly. Luckily, there are solutions that make growing weed easier, even in the comfort of one’s home. One of these solutions is Seedo, a special pod that takes care of the entire growing process and can be controlled through an app on a smartphone.

  • 7 Marijuana Penny Stocks That I May Buy
    InvestorPlace13 days ago

    7 Marijuana Penny Stocks That I May Buy

    If you invest in marijuana penny stocks, you are probably aware that over the past year many of the companies in this risky sector of the equity markets have seen significant declines in their share prices.Many of these little companies had stocks that were trading for $2 or $3 a share or even more during the ball of last year. This was due to expectations and excitement leading up to Canadian legalization. Since then, the share prices of most of these companies have fallen to just a few pennies. Once this happens, it is basically over. Very few of them will survive.The following seven companies seem to have weathered the storm over the past year. This could be an indication that they may have favorable prospects for the future. If they survive the bad times maybe they will prosper in the good times. Because of this, they are on my radar screen as potential buys.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Retail Stocks to Buy for the Second Half of 2019 Please understand that these are not recommendations. It is just a starting point for my analysis. I will be doing some more research into these companies before potentially may be making investments in them. Marijuana Penny Stocks: 48North Cannabis Corp (NRTH)48North Cannabis Corp (CVE:NRTH) produces and sells medical cannabis. It focuses on the female health and wellness market. This company is on the list because of the huge increases of trading volume that have occurred. In a situation like this, increasing volume could be a bullish signal.This is an important dynamic to understand. Stocks do not need volume to head lower, but they do need meaningful volume to go higher. This is because investors do not need to buy, but they may need to sell.For example, consider a fictional stock with every shareholder content with their positions. Buyers will not buy more, and sellers will not want to sell any.However, now suppose that one of these holders needs to raise money for an unforeseen emergency. They will be forced to sell. Because at current levels there is no buy interest, the stock will inevitably go lower because they will be forced to sell at lower prices.This increasing interest could be due to some recent news. NRTH stock's Good:House farm expects its first outdoor harvest in August, and is converting another location from cultivation to propagation, processing and packaging. This is important because outdoor marijuana is significantly cheaper to grow than greenhouse marijuana.Most marijuana is grown indoors because it is considered more secure and of better quality. But due to the huge cost advantage, investors are starting to consider outdoor growing. Two Rivers Water & Farming (TURV)Two Rivers Water & Farming (OTCMKTS:TURV) acquires and develops farmland and associated water rights. It provides greenhouses and processing facilities for marijuana growers in Colorado with water rights not used for fruit and vegetable production.TURV got my attention because the stock has been mostly trending higher since March. Maybe it is doing well because this company is different than most other penny stock companies. Two Rivers actually makes money. Last earnings report, it revealed earnings of 9 cents per share. * 10 Best Stocks for 2019: A Volatile First Half There has also been some recent positive news. The company just announced a new pilot project to manage hemp production on a large farm in Colorado. Management believes that this will pave the way for further expansion. National Access Cannabis Corp (NACNF)National Access Cannabis Corp (OTCMKTS:NACNF) is a recreational cannabis retailer in Canada.This retailer may be in a great position to profit from the enormous growth of the cannabis industry. A frequently mentioned report by Arcview Market Research and BDS Analytics states consumer spending on cannabis may increase by almost 40% this year.National Access currently operates 23 stores in Canada. Since cannabis became legal in October the company has had about $27 CAD million of sales with impressive gross margins that are around 31%.By the end of the year, the company plans to have 40 stores opened and operating. With this rate of anticipated growth, this company may have great future potential. Pivot Pharmaceuticals Inc (PVOTF)Pivot Pharmaceuticals Inc (OTCMKTS:PVOTF) is an early stage pharmaceutical company that engages in the development and commercialization of therapeutic and nutraceutical products.PVOTF has been acting well since April. This may be due to the fact the company just hired an experienced chief operating officer to strengthen its management team.The cannabis industry is full of incompetent management. Many entrepreneurs may have great ideas and can get a company up and running, but they do not have the skills to manage the company as it grows and matures. Pivot's recognition of the need for experienced people could be a good sign. * 7 A-Rated Stocks to Buy for the Rest of 2019 It also announced that it is expanding its Board of Directors. This move could attract investors. Some investors think the composition of the Board is extremely important and analyze it as part of their investment research process. Cannabics Pharmaceuticals Inc (CNBX)Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) is an early stage biotechnology company that develops personalized anti-cancer and palliative treatments.There is a very cool story here. This company is trying to develop medicinal marijuana that will treat and potentially cure cancer. But CNBX stock got my attention because it is trading at a level that has been support in the past. After finding support at these levels in December, the stock more than doubled.An important thing to consider here is that in its most recent quarter, CNBX stock reported earnings of 3 cents per share. That doesn't sound too impressive at first glance, but when you consider that most of these other penny-stock marijuana companies are losing money, you can understand the significance.Now that CNBX stock is on my radar screen, I will be watching it to see if this support holds over the next month or two. If so, I will do some more research. Earth Science Tech Inc. (ETST)Earth Science Tech Inc. (OTCMKTS:ETST) researches and develops cannabis and industrial hemp.This company holds a portfolio of diverse subsidiaries. In early June, the stock dipped to lows around 30 cents. Since then, the stock has rallied.This company caught my attention due to the extensive experience of the management team and advisory board. As I said before, many of these little marijuana companies are run by inexperienced people. ETST stock appears to be different. * 7 Retail Stocks to Buy for the Second Half of 2019 Chief Financial Officer Wendell Hecker has more than 30 years of experience in large New York City based corporations. The chief operations officer and the chief sales officer are also veterans. They each have more than two decades of experience. To see insiders with this amount of experience is unusual in this industry. Halo Labs (AGEEF)Halo Labs (OTCMKTS:AGEEF) develops and manufactures cannabis oils and concentrates.This company caught my attention because despite some volatility, it has trended higher since the beginning of the year. In January it was trading around 22 cents and the most recent close was 42 cents.There have been some developments at Halo that seem to be positive. This is what could be driving this move.Last month, the company reported that its revenues had tripled to almost $9 million. This was attributed to the launching of cannabis oil and concentrate operations in Canada and Nevada.In addition to this, AGEEF stock started trading on the OTCQX. This is one of the tiers or levels of the Canadian OTC Market. Before this, it traded on a lower tier.Because the higher tier requires more transparency and disclosure, some investors may consider this to be a positive development for the long-term prospects of the company.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy on College Students' Radars * 7 Retail Stocks to Buy for the Second Half of 2019 * The S&P 500's 5 Best Highest-Yielding Dividend Stocks The post 7 Marijuana Penny Stocks That I May Buy appeared first on InvestorPlace.

  • Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments
    PR Newswire25 days ago

    Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments

    HOD HASHARON, Israel, June 28, 2019 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that the Company and Cannabics Pharmaceuticals (CNBX) have together created and adopted a business plan for their joint venture (JV), a new entity focused on the research and development of cannabinoid formulations to treat ophthalmic conditions. Creation and approval of a business plan for the JV was a condition for the planned venture to move forward. Having assessed the regulatory pathway for eyedrops containing cannabinoids or cannabinoid strings, we are eagerly engaging in technology development and clinical advancement.

  • /C O R R E C T I O N -- Cannabics Pharmaceuticals Inc./
    PR Newswire28 days ago

    /C O R R E C T I O N -- Cannabics Pharmaceuticals Inc./

    In the news release, Cannabics Pharmaceuticals Appoints Two Independent Directors, issued June 25, 2019 by Cannabics Pharmaceuticals Inc. over PR Newswire, we are advised by the company that the 5th paragraph, 1st sentence, should read "Mr. Ballan served as Senior Executive Vice President and General Counsel at Gazit Globe, a Tel Aviv Stock Exchange listed company that is part of the TA-35 and Real-Estate 15 indexes in Israel." rather than as originally issued inadvertently. TEL AVIV, Israel and BETHESDA, Maryland, June 25, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has appointed two new independent directors to its board of directors, Dr. Estery Giloz-Ran and Eran Ballan, Esq.

  • Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada
    PR Newswire2 months ago

    Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada

    TEL AVIV, Israel and BETHESDA, Maryland, June 4, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be participating at the LIFT & Co. Conference at the Metro Toronto Convention Centre in Toronto, Canada. "This year's conference in Toronto is exciting because it is the largest premier industry business conference event in Canada," stated Mr. Barad.

  • ACCESSWIRE2 months ago

    Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California

    TEL AVIV, ISRAEL and BETHESDA, MD / ACCESSWIRE / May 30, 2019 / Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4 at 11:20AM PST at the Luxe Sunset Hotel in Bel Air, California. Mr. Eyal Barad (CEO of Cannabics Pharmaceuticals) will be presenting and meeting with investors. "This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges," stated Chris Lahiji, President at LD Micro.

  • Cannabics Pharmaceuticals' CEO to Present at the Planet MicroCap Conference in Las Vegas and at the ThinkEquity Conference in New York City
    PR Newswire3 months ago

    Cannabics Pharmaceuticals' CEO to Present at the Planet MicroCap Conference in Las Vegas and at the ThinkEquity Conference in New York City

    TEL AVIV, Israel and BETHESDA, Maryland, April 25, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, CEO, is scheduled to present at the Planet Microcap Conference in Las Vegas, Nevada, being held at the Bally's Hotel, and at the ThinkEquity Conference in New York City being held at The Mandarin Oriental Hotel. Mr. Barad is scheduled to present at the Planet MicroCap conference in Las Vegas at 2pm Pacific Time on May 1, 2019. Mr. Barad will also be speaking at the ThinkEquity conference, at 2pm Eastern Time, on May 2, 2019.

  • Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies
    PR Newswire3 months ago

    Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies

    TEL AVIV, Israel and BETHESDA, Maryland, April 17, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has obtained approval for a nationwide Israeli multisite clinical study on the antitumor properties of cannabinoid compounds on primary cancer biopsies. The apoptotic/cytotoxic effects of a multitude of cannabinoid extracts will be evaluated via Cannabics' high throughput screening platform. Dr. Eyal Ballan, CTO and Co-Founder of Cannabics, said: "We believe this is a quantum leap for the research on the biology of cancer and cannabinoids.

  • OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference
    PR Newswire4 months ago

    OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

    OTCQX and OTCQB Companies Featured at 2019 ROTH Conference NEW YORK , March 13, 2019 /PRNewswire/ --  OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, ...

  • SodaStream CEO Daniel Birnbaum to Join Seedo Board
    PR Newswire4 months ago

    SodaStream CEO Daniel Birnbaum to Join Seedo Board

    Seedo Corp. is an agro-tech company providing the world's first fully automated and controlled indoor growing machine for pesticide-free agricultural and vertical farming markets. Cannabics owns approximately 20% of Seedo Corp.'s issued and outstanding common stock.

  • Cannabics Pharmaceuticals Closes Agreement With Wize Pharma
    PR Newswire5 months ago

    Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

    BETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has closed an agreement with Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases, to form a equally owned joint venture (JV) which will focus on the research and development of cannabinoid based treatments for ophthalmic disorders.

  • Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics
    PR Newswire5 months ago

    Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics

    Companies Will Launch New Entity to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions HOD HASHARON, Israel , March 6 , 2019  /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" ...

  • Cannabics Pharmaceuticals Submits Protocol for an Ex-Vivo Clinical Study on Biopsies and Cannabinoids
    PR Newswire5 months ago

    Cannabics Pharmaceuticals Submits Protocol for an Ex-Vivo Clinical Study on Biopsies and Cannabinoids

    Cannabics has submitted a protocol for the Helsinki Committee to conduct a nationwide study on fresh biopsies treated with a multitude of cannabinoid compounds and chemotherapies TEL AVIV, Israel and BETHESDA, ...

  • Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics
    PR Newswire5 months ago

    Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics

    BETHESDA, Maryland and TEL AVIV, Israel, Feb. 7, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has entered into agreement with Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases. Initially announced in a press release on June 29, 2018, the two companies have been advancing planning and have concluded, that subject to completing a mutually agreeable business plan and obtaining an expert opinion in order to identify a potential FDA route for ophthalmic therapy containing cannabinoids, each expected to occur within 30 days, that they are ready to form a joint venture (JV) company, for the purpose of researching, developing, and administering cannabinoid formulations to treat ophthalmic disorder indications.

  • Wize Pharma, Inc. Signs Joint Venture With Cannabics, to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions
    PR Newswire5 months ago

    Wize Pharma, Inc. Signs Joint Venture With Cannabics, to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions

    HOD HASHARON, Israel, Feb. 7, 2019 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that the Company has signed an agreement to form a joint venture (JV) company for the purpose of researching, developing and administering cannabinoid formulations to treat ophthalmic conditions  with Cannabics Pharmaceuticals Inc. ("Cannabics") (OTCQB: CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects. The agreement will become effective subject to receipt of an expert opinion, within 30 days from the date of signing, describing the regulatory pathway for eye drops containing cannabinoids.  Upon effectiveness, Wize shall issue 900,000 shares of its common stock to Cannabics and Cannabics shall issue 2,263,944 shares of its common stock to Wize.  The agreement shall expire if the parties have not approved a business plan by June 30, 2019.

  • Cannabics Pharmaceuticals Files Four New Provisional Patent Applications for Cannabinoid-Based Drugs and Treatments for Non-Epileptic Seizures and Tremors
    PR Newswire6 months ago

    Cannabics Pharmaceuticals Files Four New Provisional Patent Applications for Cannabinoid-Based Drugs and Treatments for Non-Epileptic Seizures and Tremors

    TEL AVIV, Israel and BETHESDA, Maryland, Jan. 31, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that it has filed an additional four provisional patent applications with the Israel Patent Office, for cannabinoid-based drugs and treatments, designed for conditions associated with non-epileptic seizures and tremors. Dr. Eyal Ballan and Eyal Barad, co-founders of Cannabics, believe that the company's clinical experience and personalization platform may allow for personalized cannabinoid solutions for conditions and syndromes such as Alcohol Withdrawal Syndrome (AWS), REM related sleep disorder (RBD), Psychogenic non-epileptic seizures (PNES) and Drug-induced tremors, found as extrapyramidal side effects (EPSE).

  • Cannabics Pharmaceuticals and NewCanna Hub Intend to Collaborate to Manufacture and Market Cannabics' SR Capsules in Colombia
    PR Newswire6 months ago

    Cannabics Pharmaceuticals and NewCanna Hub Intend to Collaborate to Manufacture and Market Cannabics' SR Capsules in Colombia

    TEL AVIV, Israel and BETHESDA, Maryland, Jan. 24, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects announced, that NewCanna Hub, a world leader in the field  of cannabinoids, have signed a non-binding letter of intent ("LOI") today at The World Economic Forum, in Davos, Switzerland, to establish an equal joint venture that is intended to produce and market Cannabics' Slow Release ("SR") capsules in Colombia and, potentially, other regulated markets. Pursuant to the terms of the LOI, the parties intend to develop a joint business plan for the joint venture within the next 30 days and execute a definitive joint venture agreement as soon as reasonably practicable. As part of the new proposed joint venture, the SR capsules are expected to be produced at NewCanna's Good Manufacturing Practice (GMP) certified facility in Columbia in various formulations.

  • Cannabics Pharmaceuticals to Co-Sponsor the Canada Cannabis House at the World Economic Forum in Davos
    PR Newswire6 months ago

    Cannabics Pharmaceuticals to Co-Sponsor the Canada Cannabis House at the World Economic Forum in Davos

    TEL AVIV, Israel and BETHESDA, Maryland, Jan. 22, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, Co-Founder and CEO, and Dr. Eyal Ballan, Co-Founder and CTO, will be in Davos, Switzerland in January, 2019.

  • Cannabics Pharmaceuticals Converts $1 Million Loan Into Common Shares of Seedo
    PR Newswire6 months ago

    Cannabics Pharmaceuticals Converts $1 Million Loan Into Common Shares of Seedo

    TEL AVIV, Israel, Jan. 8, 2019 /PRNewswire/ -- Seedo Corp. (SEDO), a high-tech company providing the world's first fully automated and controlled indoor growing machine for the organic cannabis and agriculture markets, today announced that U.S.-based partner and investor Cannabics Pharmaceuticals Inc., a leader in personalized cannabinoid medicine focused on cancer and its side effects, is converting its $1 million convertible loan to Seedo into common shares of the company.

  • Cannabics Pharmaceuticals to be present during the J.P. Morgan Healthcare Conference In San Francisco
    PR Newswire7 months ago

    Cannabics Pharmaceuticals to be present during the J.P. Morgan Healthcare Conference In San Francisco

    TEL AVIV, Israel and BETHESDA, Md., Dec. 31, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, CEO, will be in San Francisco in January 2019 during the J.P. Morgan Healthcare Conference. The company will be meeting with Investors as well as potential partners such as Pharmaceuticals and Biotech firms from Monday, January 7th to Wednesday, January 9th. Mr. Barad will provide an overview on the company's mission and provide insight into the path forward towards bringing a highly valuable and needed solution to cancer patients.

  • Cannabics Pharmaceuticals Announces New Provisional Patent Application for Personalized Cannabimetic Compositions Modeling and Production
    PR Newswire7 months ago

    Cannabics Pharmaceuticals Announces New Provisional Patent Application for Personalized Cannabimetic Compositions Modeling and Production

    TEL AVIV, Israel and BETHESDA, Maryland, Dec. 26, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has filed a provisional patent application with the US Patent office. The patent covers the Company's technology that will enable the transfer of data from its proprietary personalization platform of cannabis strains and cancer to medical cannabis businesses worldwide and overcome the limitations of exporting and importing cannabinoid compounds due to regulation.

  • Market Exclusive7 months ago

    Cannabis Stock News Daily Roundup December 12

    Cannabis News New York-based medical cannabis firm Columbia Care has received approval and license from the State of Virginia to produce cannabis oil. The company, recently valued at $1.35 billion, is planning to open its dispensary in Portsmouth, Virginia, in the spring of 2019. They plan to cultivate, produce and dispense cannabidiol (CBD) and tetrahydrocannabinolic […] The post Cannabis Stock News Daily Roundup December 12 appeared first on Market Exclusive.

  • Cannabics Pharmaceuticals Prepares ISO Application for Its Diagnostics Platform Towards Commercialization
    PR Newswire7 months ago

    Cannabics Pharmaceuticals Prepares ISO Application for Its Diagnostics Platform Towards Commercialization

    TEL AVIV, Israel and BETHESDA, Maryland, Dec. 11, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has started the accreditation process in accordance with ISO 15189:2012 for its drug screening and diagnostics laboratory, which it expects to receive by the end of next year. ISO is the accepted "International Organization for Standardization", and ISO 15189:2012 is the international standard for quality management and competence for Medical Laboratories by regulators and accrediting bodies.

  • Market Exclusive8 months ago

    Cannabis Stock News Daily Roundup November 29

    The global legal cannabis market is projected to hit $146.4 billion by end of 2025, according to research by Grand View Research. The legal cannabis industry is gaining traction worldwide due to high demand among consumers for recreational and medical products. Recreational cannabis spending is projected to hit $35 Billion mark, while medical cannabis spending […] The post Cannabis Stock News Daily Roundup November 29 appeared first on Market Exclusive.